flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 FLOW: outcome results for GLP-1RA FLOWing with the SemagluTIDE —

CMS has issued guidance to Medicare Part D plans stating that anti-obesity medications that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use, the spokesperson explained, adding that Medicare coverage is still not available to patients only taking the drug to lose weight

Macklin receives honoraria and consulting fees and serves on the national advisory boards for the manufacturers of Novo Nordisk and Eli Lilly, which makes Mounjaro, a different Type 2 diabetes drug also used for weight loss

Smooth process, good experience

This makes it particularly interesting for central obesity, metabolic syndrome, and body composition optimization

Other tests may be indicated such as lactate, electrolytes, and serum creatinine